



Press release from Emotra AB (publ)

Göteborg, July 18, 2017

EMOTRA AB: Final day for trading in PSS (BTA)

Emotra AB ("Emotra") carried out a rights issue of shares in June, 2017. This new share issue, encompassing 4,184,399 shares, was also open to the general public. The last day for trading in PSS (Paid Subscribed Shares) is July 20, 2017 and the stop date is July 24, 2017.

4,184,399 shares have been registered with Bolagsverket (The Swedish Companies Registration Office) and we expect these shares to be distributed to the respective accounts/deposits of securities on July 26, 2017. After registration with Bolagsverket, Emotra's share capital will amount to 2,534,917.92 SEK, divided among 13,702,259 shares.

Financial Advisor

Emotra's Financial Advisor in connection with this rights issue was Sedermera Fondkommission.

For questions related to this rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 40 615 14 10
E-mail: info@sedermera.se

For further information about Emotra, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se